100 related articles for article (PubMed ID: 1510728)
1. Lack of enantio-selectivity in the in vitro antitumour cytotoxicity and membrane-damaging activity of ether lipid SRI 62-834: further evidence for a non-receptor-mediated mechanism of action.
Lohmeyer M; Workman P
Biochem Pharmacol; 1992 Aug; 44(4):819-23. PubMed ID: 1510728
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric flow cytometry of the modulation of tumor cell membrane permeability by developmental antitumor ether lipid SRI 62-834 in EMT6 mouse mammary tumor and HL-60 human promyelocytic leukemia cells.
Dive C; Watson JV; Workman P
Cancer Res; 1991 Feb; 51(3):799-806. PubMed ID: 1988120
[TBL] [Abstract][Full Text] [Related]
3. The role of intracellular free calcium mobilization in the mechanism of action of antitumour ether lipids SRI 62-834 and ET18-OMe.
Lohmeyer M; Workman P
Biochem Pharmacol; 1993 Jan; 45(1):77-86. PubMed ID: 8424826
[TBL] [Abstract][Full Text] [Related]
4. Platelet-activating factor (PAF) antagonist WEB 2086 does not modulate the cytotoxicity of PAF or antitumour alkyl lysophospholipids ET-18-O-methyl and SRI 62-834 in HL-60 promyelocytic leukaemia cells.
Workman P; Donaldson J; Lohmeyer M
Biochem Pharmacol; 1991 Jan; 41(2):319-22. PubMed ID: 1989642
[No Abstract] [Full Text] [Related]
5. Growth arrest vs direct cytotoxicity and the importance of molecular structure for the in vitro anti-tumour activity of ether lipids.
Lohmeyer M; Workman P
Br J Cancer; 1995 Aug; 72(2):277-86. PubMed ID: 7640206
[TBL] [Abstract][Full Text] [Related]
6. Two different sites of action for platelet activating factor and 1-O-alkyl-2-O-methyl-sn-glycero-3-phosphocholine on platelets and leukemic cells.
Salari H; Dryden P; Howard S; Bittman R
Biochem Cell Biol; 1992 Feb; 70(2):129-35. PubMed ID: 1324692
[TBL] [Abstract][Full Text] [Related]
7. Is metabolism an important arbiter of anticancer activity of ether lipids? Metabolism of SRI 62-834 and hexadecylphosphocholine by [31P]-NMR spectroscopy and comparison of their cytotoxicities with those of their metabolites.
Bishop FE; Dive C; Freeman S; Gescher A
Cancer Chemother Pharmacol; 1992; 31(2):85-92. PubMed ID: 1451237
[TBL] [Abstract][Full Text] [Related]
8. Continuous binding of the PAF molecule to its receptor is necessary for the long-term aggregation of platelets.
Suzuki M; Sugatani J; Ino M; Shimura M; Akiyama M; Yamazaki R; Suzuki Y; Miwa M
Am J Physiol; 1998 Jan; 274(1):C47-57. PubMed ID: 9458712
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of SRI 62-834, a cyclic ether analog of ET-18-OCH3.
Houlihan WJ; Lee ML; Munder PG; Nemecek GM; Handley DA; Winslow CM; Happy J; Jaeggi C
Lipids; 1987 Nov; 22(11):884-90. PubMed ID: 2832680
[TBL] [Abstract][Full Text] [Related]
10. Elevation of leukemic cell intracellular calcium by the ether lipid SRI 62-834.
Lazenby CM; Thompson MG; Hickman JA
Cancer Res; 1990 Jun; 50(11):3327-30. PubMed ID: 2334926
[TBL] [Abstract][Full Text] [Related]
11. 1-O-hexadecyl-2-metoxy-glycero-3-phosphatidylcholine--a methoxy ether lipid inhibiting platelet activating factor-induced platelet aggregation and neutrophil oxidative metabolism.
Le Blanc K; Samuelsson J; Brohult J; Berg A; Palmblad J
Biochem Pharmacol; 1995 May; 49(11):1577-82. PubMed ID: 7786298
[TBL] [Abstract][Full Text] [Related]
12. Membrane peroxidative damage enhancement by the ether lipid class of antineoplastic agents.
Wagner BA; Buettner GR; Burns CP
Cancer Res; 1992 Nov; 52(21):6045-51. PubMed ID: 1394229
[TBL] [Abstract][Full Text] [Related]
13. Pharmacology of a potent platelet-activating factor antagonist: Ro 24-4736.
Crowley HJ; Yaremko B; Selig WM; Janero DR; Burghardt C; Welton AF; O'Donnell M
J Pharmacol Exp Ther; 1991 Oct; 259(1):78-85. PubMed ID: 1656030
[TBL] [Abstract][Full Text] [Related]
14. Beneficial effects of TCV-309, a novel potent and selective platelet activating factor antagonist in endotoxin and anaphylactic shock in rodents.
Terashita Z; Kawamura M; Takatani M; Tsushima S; Imura Y; Nishikawa K
J Pharmacol Exp Ther; 1992 Feb; 260(2):748-55. PubMed ID: 1738121
[TBL] [Abstract][Full Text] [Related]
15. Effects of ether lipid 1-O-octadecyl-2-methoxy-rac-glycero- 3-phosphocholine and its analogs PAF and CPAF on the release of nitric oxide in primary cultures of rat astrocytes.
Cardile V; Jiang X; Renis M; Bindoni M
Brain Res; 1996 Apr; 715(1-2):98-103. PubMed ID: 8739627
[TBL] [Abstract][Full Text] [Related]
16. Influence of platelet activating factor antagonists on the protamine sulphate stimulated release of histamine from peritoneal mast cells of rats in vitro.
Lohde C; Bahr T; Labes D; Grupe R
Arzneimittelforschung; 1992 Jan; 42(1):27-31. PubMed ID: 1375025
[TBL] [Abstract][Full Text] [Related]
17. Antitumor activity of synthetic alkylphospholipids with or without PAF activity.
Kudo I; Nojima S; Chang HW; Yanoshita R; Hayashi H; Kondo E; Nomura H; Inoue K
Lipids; 1987 Nov; 22(11):862-7. PubMed ID: 3444379
[TBL] [Abstract][Full Text] [Related]
18. Formation of a highly stable complex between BN 50730 [tetrahydro-4,7,8,10 methyl-1(chloro-2 phenyl)-6 (methoxy-4 phenyl-carbamoyl)-9 pyrido [4',3'-4,5] thieno [3,2-f] triazolo-1,2,4 [4,3-a] diazepine-1,4] and the platelet-activating factor receptor in rabbit platelet membranes.
Silva CL; Cruz HN; Violante FA; Cordeiro RS; Martins MA; Noël F
Biochem Pharmacol; 1996 Jan; 51(2):193-6. PubMed ID: 8615889
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the R- and S-enantiomers of RS-2-[[hydroxy[[2-[ (octadecyloxy)methyl]tetrahydrofuran-2-yl]methoxy]-phosphinyl]oxy]-N, N,N,-trimethylethylaminium hydroxide inner salt.
Houlihan WJ; Prasad K; Underwood R; Repic O; Munder PG
J Med Chem; 1996 Jan; 39(2):605-8. PubMed ID: 8558533
[TBL] [Abstract][Full Text] [Related]
20. Role of endocytosis in the action of ether lipids on WEHI-3B, HL60, and FDCP-mix A4 cells.
Bazill GW; Dexter TM
Cancer Res; 1990 Dec; 50(23):7505-12. PubMed ID: 2253199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
